Miach Orthopaedics

Miach Orthopaedics is a medical device company specializing in bio-engineered solutions for anterior cruciate ligament (ACL) injury treatment. Founded in 2016 by Dr. Martha Murray at Boston Children's Hospital, the company developed the BEAR® (Bridge-Enhanced ACL Restoration) Implant, which represents a paradigm shift from traditional ACL reconstruction to natural tissue restoration. The BEAR Implant received FDA De Novo approval in 2020—the first such approval in sports medicine—and is now shown to reduce the risk of post-traumatic osteoarthritis. The implant works by creating a protective environment that enables the body to regenerate its own ACL tissue by forming a blood clot between torn ACL ends. Miach Orthopaedics actively supports healthcare professionals with clinical evidence, surgical training, rehabilitation protocols, and patient education resources. The company conducts ongoing clinical studies including the BEAR Implant Registry Study and BEAR MOON Study to track long-term outcomes and supports a network of surgeons and physical therapists across the United States.